Glaxosmithkline Pharmaceuticals Ltd.

GLAXO

Market Cap
₹35,233 Cr.
P/E
66.61

Glaxosmithkline Pharmaceuticals Ltd.

Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics
Other Income
Other Income is not affecting ratios of the company
Pledge
Promoters have not pledged a significant portion of their holding
Revenue Recognition
Company is converting accounting profit to cash
Depreciation Effect
Depreciation accounting is not leading to increase in profits
Capex vs ROCE
ROCE of the company has increased over the last three years
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been buying the stock which is usually a sign of exuberance
Share price
Share price has increased over last 10 years but more due to rerating
ROE
Net Profit Margin is responsible for ROE increase over last 10 years
Working Capital
Working Capital of the company seems to be under control
Debt
Company should not have issues servicing its debt
Promoter Holding
Promoter has not sold any shares in the last 90 days
Current vs Historic Valuation
Company is trading at a premium to 3 year historic valuations
ROE
Latest
35.07%
3yr Average
40.98%
5yr Average
29.77%
Net Profit Margin
Latest
18.78%
3yr Average
27.57%
5yr Average
19.97%
ROCE
Latest
44.96%
3yr Average
36.75%
5yr Average
31.2%
Debt to Equity
Latest
-
3yr Average
0.0
5yr Average
0.0
Market Share
0% (as of Jul 22)
Anti - Diabetes - Market Share
5.97% (as of Jul 22)
Anti-Infectives - Market Share
1.14% (as of Nov 21)
Antineo Plastic - Market Share
13.90% (as of Mar 22)
Augmentin - Market Share
locked Source
3.40% (as of Mar 22)
Betnesol - Market Share
locked Source
5.80% (as of Mar 22)
Betnovate C - Market Share
locked Source
6.10% (as of Mar 22)
Betnovate N - Market Share
locked Source
0.64% (as of Nov 21)
Blood Related - Market Share
9.30% (as of Mar 22)
Calpol - Market Share
locked Source
0.08% (as of Jul 22)
Cardiovascular - Market Share
5.60% (as of Mar 22)
Ceftum - Market Share
locked Source
10.50% (as of Nov 21)
Dermatology - Market Share
5.20% (as of Mar 22)
Eltroxin - Market Share
locked Source
11.80% (as of Nov 21)
Endocrinology - Market Share
0.09% (as of Jul 22)
Gastro-Intestinal - Market Share
0.24% (as of Nov 21)
Gynecology - Market Share
0.01% (as of May 20)
Neurological - Market Share
0.79% (as of Nov 21)
Ophthalmology - Market Share
3.25% (as of Nov 21)
Pain - Market Share
2.60% (as of Dec 22)
Pharmaceutical Sector - Market Share
2.23% (as of Nov 21)
Respiratory - Market Share
3% (as of Nov 21)
Stomatological - Market Share
2.80% (as of Mar 22)
Synflorix - Market Share
locked Source
6.20% (as of Mar 22)
T Bact - Market Share
locked Source
1.21% (as of Jan 20)
Urology - Market Share
24.13% (as of Jul 22)
Vaccines - Market Share
1.92% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
5.20% (as of Mar 19)
Zinetac - Market Share
locked Source
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Wise Break-Up - Domestic

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Acute vs Chronic

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • Domestic Sales Growth - YoY (%)
      Source
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Brands
    Augmentin
    Betnesol
    Calpol
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline